Lung cancer kills more people than any other cancer. And while immunotherapy and targeted therapy are exciting, chemotherapy remains essential — especially for small cell lung cancer (SCLC) and advanced non‑small cell lung cancer (NSCLC). The chemotherapy market forecast shows that lung cancer is the fastest‑growing indication, with a CAGR above 7.5%. Why? Because rates are rising in Asia, and new drug combinations are improving survival.

What's new? Platinum‑doublet chemotherapy (carboplatin + paclitaxel or pemetrexed) remains standard, but now it's often combined with immunotherapy (Keytruda, Tecentriq) for better results. The chemotherapy market analysis notes that the fastest‑growing route of administration is intravenous (still), but subcutaneous delivery is emerging — a shot under the skin instead of an IV.

But chemo for lung cancer has a bad reputation for side effects (fatigue, low blood counts). That's why growth factors (Neulasta) are used to boost white cells, and better anti‑nausea drugs (Emend, Akynzeo) are standard.

The message: if you have advanced lung cancer, don't dismiss chemo. It's not a cure, but it can shrink tumours, relieve symptoms, and give you more time. And with supportive care, the side effects are manageable.